ArticleScientific reports2026
Investigation of the effects of a Kiperin Bromelain & Papain complex in normal colon, mammary, and skin cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bromelain is a proteolytic enzyme complex naturally found in the stem, fruit, and juice of pineapple, while papain is a proteolytic enzyme derived from the latex of the papaya plant. These bioactive components have attracted increasing scientific interest due to their reported roles in cell proliferation and wound healing, suppression of oxidative stress through free radical scavenging, and apoptosis-related pathways. Although bromelain and papain have been associated with various health-related effects, their effects on healthy cells remain largely unexplored. In this study, different concentrations of Kiperin Bromelain & Papain (KBP) (1.0-3.5 µg/mL) were tested in healthy cell lines. Based on the concentration showing the highest cell viability, 2.5 µg/mL was selected for further analyses, and CCD-18Co (colon fibroblasts), HME-1 (mammary epithelial cells), and HaCaT (keratinocytes) were treated accordingly. Cell viability was assessed by cell counting, and wound healing was evaluated. Gene expression levels of MMP9, IVL, FLG, IL-6, IL-10, NFKβ, and TNF-α were measured by real-time PCR. KBP exposure increased cell viability in all cell lines, with the most pronounced effect observed at 2.5 µg/mL. Wound-healing assays indicated changes in wound closure following KBP exposure. In addition, KBP treatment was associated with decreased expression of inflammation-related genes (IL-6, IL-10, NFKβ, and TNF-α) and increased expression of genes related to skin barrier/keratinization (IVL and FLG). The magnitude of these effects differed across cell types, indicating cell-specific responses. Further research is warranted to validate these findings in in vivo models and to clarify the potential applications of KBP in dermatological contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.